Oculus Innovative Sciences Inc (OCLS.OQ) Company Profile | Reuters.com
Edition:
United States

Profile: Oculus Innovative Sciences Inc (OCLS.OQ)

OCLS.OQ on NASDAQ Stock Exchange Capital Market

4.00USD
29 Jun 2016
Change (% chg)

$-0.12 (-2.91%)
Prev Close
$4.12
Open
$4.11
Day's High
$4.27
Day's Low
$3.80
Volume
14,263
Avg. Vol
9,883
52-wk High
$9.65
52-wk Low
$3.80

Oculus Innovative Sciences, Inc., incorporated on November 20, 2006, is a specialty device and pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals. The Company offers wound care products which are sold into the human and animal healthcare markets in the United States, Mexico and Europe. The Company also operates a microbiology contract testing laboratory division that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs, as well as testing of products and the Company's products.

The Company's key technology, Microcyn is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. The pathogens include viruses, fungi, spores and bacteria, including antibiotic-resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), as well as Clostridium difficile (C. diff). The Company completed Phase II trials for Microcyn technology.

The Company offers a range of products to the customers in the United States market. The Company offers products, such as Microcyn Skin and Wound Care with preservatives, which manages wounds through debridement of wounds, such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites; Microcyn Skin and Wound HydroGel, which is used on first and second degree burns, exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and for the management of mechanically or surgically debrided wounds; Alevicyn Dermal Spray, which is used for cleansing, irrigation, moistening, debridement and removal of foreign material, including microorganisms and debris from exudating wounds, acute and chronic dermal lesions, including stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites, and exit sites; Alevicyn Antipuritic Gel, which manages itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue; Celacyn Prescription Scar Management Gel, which manages old and new hypertrophic and keloid scarring on scars resulting from burns, general surgical procedures and trauma wounds, and MicrocynAH hydrogel and wound and skin care products, which manages animal wounds, such as hot spots, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin and lacerations.

The Company offers a range of products to the customers in Mexico market. The Company offers products, such as Microdacyn Antiseptic, a wound care antiseptic; Baby Microdacyn, which is used for the treatment of diaper rash and rosaduras in children; Gramaderm Solution and Gramaderm Gel, which are used as an adjunct in the tropical treatment of mild to moderate acne; Pediacyn, which is used in the care of lesions associated with atopic dermatitis; Epicyn, which is used in the management and reduction of new and existing hypertrophic and keloid scars, and Microdacyn Bucofaringeo, which is used as an adjunct in the treatment of both mouth and throat infections.

The Company offers a range of products to the customers in Europe market. The Company offers products, such as Microdacyn60 Wound Care, which is used in the debridement and moistening of acute and chronic wounds, ulcers, cuts, abrasions and burns, including those located in any human cavity, such as the oral, nasal or ear; Microdacyn Wound Care Hydrogel, which is used in the debridement and moistening of acute and chronic wounds, ulcers, cuts, abrasions and burns, including those in the mouth, nose and ear; Gramaderm Solution and Gramaderm Gel, which are used as an adjunct in the tropical treatment of mild to moderate acne; Pediacyn, which is engaged in the care of lesions associated with atopic dermatitis, and Epicyn, which is engaged in the management and reduction of new and existing hypertrophic and keloid scars.

The Company competes with Kinetic Concepts Inc., Smith & Nephew, Shire Regenerative Medicine, Integra Life Sciences, Life Cell, Organogenesis, Ortec International, Celleration, Animal Health International, Inc., Henry Schein, Inc., Innovacyn, Inc. and Patterson Companies, Inc.

Company Address

Oculus Innovative Sciences Inc

1129 N Mcdowell Blvd
PETALUMA   CA   94954-1110
P: +1707.7820792
F: +1707.2830551

Company Web Links